Recent News

• 05.07.2026 - Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
• 04.28.2026 - Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
• 04.06.2026 - Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
• 04.06.2026 - Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
• 04.06.2026 - Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
• 02.26.2026 - Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

Recent Filings

• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4/A Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4/A Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4/A Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4/A Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4/A Statement of changes in beneficial ownership of securities